| Stock Name | iShares Healthcare Innovation UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| ETF Ticker | DRDR(GBX) LSE |
| ETF Ticker | 2B78(EUR) F |
| ETF Ticker | 2B78.DE(EUR) CXE |
| ETF Ticker | DRDR.LS(GBX) CXE |
| ETF Ticker | HEAL.AS(EUR) CXE |
| ETF Ticker | HEAL.LS(USD) CXE |
| ETF Ticker | HEALz(USD) CXE |
| ETF Ticker | HEAL(EUR) ETF Plus |
| ETF Ticker | DRDR.L(GBP) LSE |
| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|---|---|---|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Warning: Undefined variable $fallen in /var/www/liquidata/show_ETF_trades.php on line 177 however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 17.7747 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 17.7747. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -17.6% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 48,711 (USD $34) compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 31.3469 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 31.3469. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 56.6% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 26,050 (USD $18) compared to the previous valuation of Oscotec Inc. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 119.6 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 119.6. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in 068270.KS has increased by KRW 117,491 (USD $81) compared to the previous valuation of CELLTRION INC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 17.8781 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 17.8781. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 18,229 (USD $13) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 3.05897 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 3.05897. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 14,399 (USD $1,852) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.29677 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.26737 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.26737. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 48.4% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 21,847 (USD $2,809) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 841.199 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 841.199. The average price that 207940.KS shares were previous bought at was KRW 720.393. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in 207940.KS has increased by KRW 62,438 (USD $43) compared to the previous valuation of SAMSUNG BIOLOGICS LTD however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.58955 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.58955. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 45.1% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 44,458 (USD $5,717) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 3.17989 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 3.17989. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -16.0% lower than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 4,052 (USD $521) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 66.483 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 66.483. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 11,108 (USD $8) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 69.2387 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 69.2387. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 72.3% higher than average price they were purchased at. The value of the holding in 298380.KQ has fallen by KRW 12,470 (USD $9) compared to the previous valuation of ABL Bio Inc. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 37.4096 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 37.4096. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in 302440.KS has increased by KRW 13,298 (USD $9) compared to the previous valuation of SK BIOSCIENCE LTD however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 82.3286 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 82.3286. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 94,007 (USD $65) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 30.0034 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 30.0034. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -18.8% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 8,698 (USD $6) compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.60924 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.60924. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -7.8% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 8,291 (USD $1,066) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 28.5112 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 28.5112. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 47,653 (USD $310) compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.0605 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.0605. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 1,044 (USD $7) compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 9.79908 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 9.79908. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 20,800 (USD $135) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.2821 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.2821. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 11,818 (USD $77) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.85542 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.85542. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 6,257 (USD $41) compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.8313 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.8313. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -39.4% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 88,330 (USD $574) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 33.1851 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 33.1851. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in 6951.T has fallen by JPY 3,590 (USD $23) compared to the previous valuation of JEOL Ltd. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.52969 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.52969. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 680 (USD $4) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.4141 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.4141. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 495,834 (USD $3,224) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 15.6675 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 15.6675. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 7,990 (USD $52) compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 10.8248 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 10.8248. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 30,286 (USD $3,895) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 146.36 | USD 0 | The current share valuation price of A based on adjusted close was USD 146.36. The average price that A shares were previous bought at was USD 118.65. The current market price is 23.4% higher than average price they were purchased at. The value of the holding in A has fallen by USD 47,232 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 218.71 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 218.71. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 14.4% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 35,570 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 4.03 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 4.03. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 31,152 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 125.89 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 125.89. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in ABT has fallen by USD 52,483 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 22.2 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 22.2. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 55,410 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 85.69 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 85.69. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 34.3% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 43,483 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 14.71 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 14.71. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 132.4% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 14,955 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 32.65 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 32.65. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in ALKS has fallen by USD 47,960 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 323.66 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 323.66. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 176,623 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.18 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.18. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in AMLX has fallen by USD 11,799 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 33.98 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 33.98. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 48.4% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 149,955 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 8.78001 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 8.78001. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -46.6% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 1,602 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.19 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.19. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in ARVN has increased by USD 48,475 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 22.43 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 22.43. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is -17.3% lower than average price they were purchased at. The value of the holding in ASTH has fallen by USD 154,020 compared to the previous valuation of Astrana Health Inc |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 31.99 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 31.99. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in ATRC has fallen by USD 3,644 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 14.89 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 14.89. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 69.1% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 45,650 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 24 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 24. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 42.4% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 23,240 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 137.8 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 137.8. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 30.5% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 16,305 compared to the previous valuation of Axsome Therapeutics Inc |
| BANB.SW - | HOLD | 0 @ CHF 63.4881 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 63.4881. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is -2.5% lower than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 6,773 (USD $8,392) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 29.3645 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 29.3645. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 17.9% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 1,623 (USD $251) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.2 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.2. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 27,772 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 21.65 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 21.65. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 68,256 compared to the previous valuation of Beam Therapeutics Inc |
| BIIB - Biogen Inc | HOLD | 0 @ USD 156.26 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 156.26. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 82,956 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 122.97 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 122.97. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 23,154 (USD $26,729) compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 307.38 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 307.38. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 47,340 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 307.38 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 307.38. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 47,340 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 27.9534 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 27.9534. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 19.7% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 15,979 (USD $1,675) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 26.29 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 26.29. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in BLFS has increased by USD 20,751 compared to the previous valuation of BioLife Solutions Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 47.26 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 47.26. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -13.3% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 170,976 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.91 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.91. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 134,169 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.91 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.91. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 134,169 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 16.7 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 16.7. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in CDNA has increased by USD 68,327 compared to the previous valuation of Caredx Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 8.62 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.62. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is -18.4% lower than average price they were purchased at. The value of the holding in CERT has fallen by USD 7,177 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 40.22 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 40.22. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 21.3% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 40,085 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 113.577 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 113.577. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 55.1% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 129,684 (USD $20,049) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 21.56 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 21.56. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in CPRX has increased by USD 25,131 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CRL - Creightons Plc | HOLD | 0 @ USD 168.97 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 168.97. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in CRL has increased by USD 55,238 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 75.62 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 75.62. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 12,765 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 34.74 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 34.74. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 77.7% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 60,440 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 4.75 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 4.75. The average price that CTKB shares were previous bought at was USD 5.75945. The current market price is -17.5% lower than average price they were purchased at. The value of the holding in CTKB has increased by USD 20,993 compared to the previous valuation of Cytek Biosciences Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 10.16 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 10.16. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is 37.9% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 40,340 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 211.17 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 211.17. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 90,933 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 211.17 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 211.17. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 90,933 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 68.1244 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 68.1244. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 13,048 (USD $15,062) compared to the previous valuation of DiaSorin SpA |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.04 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.04. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -15.0% lower than average price they were purchased at. The value of the holding in DVAX has increased by USD 30,564 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 54.84 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 54.84. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -31.2% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 28,279 compared to the previous valuation of DexCom Inc |
| DYVOX.ST - | HOLD | 0 @ SEK 9.73752 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 9.73752. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 61.8% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 8,680 (USD $910) compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 4.56446 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 4.56446. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is -17.9% lower than average price they were purchased at. The value of the holding in EKTA-B.ST has fallen by SEK 16,016 (USD $1,679) compared to the previous valuation of |
| EMBC - Embecta Corp | HOLD | 0 @ USD 13.67 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 13.67. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -10.7% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 8,497 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.0587 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.0587. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -10.0% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 3,382 (USD $3,904) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.95 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.95. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -53.2% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 1,303 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.00418 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.00418. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in EVT.DE has fallen by EUR 10,183 (USD $11,755) compared to the previous valuation of Evotec SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.08 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.08. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in EW has increased by USD 136,350 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 66.58 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 66.58. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 28.2% higher than average price they were purchased at. The value of the holding in EXAS has increased by USD 91,999 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 41.41 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 41.41. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 199,396 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 11.18 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 11.18. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 7,960 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 97.92 | USD 0 | The current share valuation price of GH based on adjusted close was USD 97.92. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 128.5% higher than average price they were purchased at. The value of the holding in GH has increased by USD 181,884 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 118.15 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 118.15. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 93,877 compared to the previous valuation of Guild Esports Plc |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 32.0069 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 32.0069. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 43,944 (USD $50,728) compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 290.011 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 290.011. The average price that GMAB.CO shares were previous bought at was DKK 214.002. The current market price is 35.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 239,740 (USD $37,063) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.2991 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.2991. The average price that GSK.L shares were previous bought at was GBP 18.3574. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 27,320 (USD $35,906) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.01 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.01. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 34,584 compared to the previous valuation of Halozyme Therapeutics Inc |
| HLUN-B.CO - | HOLD | 0 @ DKK 7.18726 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 7.18726. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 47,915 (USD $7,407) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.3 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.3. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 45,986 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 31.82 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 31.82. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in HRMY has increased by USD 21,094 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 12.18 | USD 0 | The current share valuation price of IART based on adjusted close was USD 12.18. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -43.5% lower than average price they were purchased at. The value of the holding in IART has increased by USD 11,578 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.16 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.16. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -24.2% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 8,463 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 30.89 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 30.89. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 40.4% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 68,998 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 121.72 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 121.72. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 31.3% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 30,638 compared to the previous valuation of Illumina Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.37 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.37. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in IOVA has increased by USD 23,869 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 146.641 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 146.641. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 26.7% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 150,314 (USD $173,521) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 213.05 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 213.05. The average price that IQV shares were previous bought at was USD 158. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 242,831 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 576.2 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 576.2. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 458,784 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 27.59 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 27.59. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in JANX has increased by USD 75,555 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 188.41 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 188.41. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 21.2% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 176,180 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 39.5 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 39.5. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 57,982 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.32 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.32. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 44,291 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.17 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.17. The average price that LAB shares were previous bought at was USD 1.33. The current market price is -12.0% lower than average price they were purchased at. The value of the holding in LAB has increased by USD 17,026 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 209.29 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 209.29. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 86.5% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 159,176 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 50.88 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 50.88. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in LIVN has increased by USD 28,443 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 50.69 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 50.69. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -40.6% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 31,892 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 662.161 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 662.161. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 65,683 (USD $81,383) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 92.66 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 92.66. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 78,373 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 600.44 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 600.44. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 79.7% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 330,368 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 83.08 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 83.08. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 69,159 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.75. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 86,541 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.75. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 86,541 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.76 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.76. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in MRNA has increased by USD 103,823 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 95.42 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 95.42. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 83.2% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 14,483 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.1 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.1. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 36,885 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.48 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.48. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in MYGN has increased by USD 20,124 compared to the previous valuation of Myriad Genetics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 150.02 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 150.02. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 282,063 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 6.36 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 6.36. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -40.3% lower than average price they were purchased at. The value of the holding in NEOG has fallen by USD 10,579 compared to the previous valuation of Neogen Corporation |
| NEU.AX - | HOLD | 0 @ AUD 12.1663 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.1663. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 87.3% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 21,453 (USD $13,950) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 126.728 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 126.728. The average price that NOVN.SW shares were previous bought at was CHF 105.855. The current market price is 19.7% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 2,421 (USD $3,000) compared to the previous valuation of |
| NTRA - Natera Inc | HOLD | 0 @ USD 206.63 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 206.63. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 29.8% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 639,876 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 4.64 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 4.64. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 38.5% higher than average price they were purchased at. The value of the holding in NUVB has fallen by USD 26,931 compared to the previous valuation of Nuvation Bio Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.11 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.11. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 61,235 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.11 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.11. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 61,235 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 11.27 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 11.27. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -51.5% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 42,861 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.81581 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.81581. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in ONT.L has fallen by GBP 18,107 (USD $23,797) compared to the previous valuation of Oxford Nanopore Technologies Ltd |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.76 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.76. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 34.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pacific Biosciences of California |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.39 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.39. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 24,669 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.68002 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.68002. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 103.7% higher than average price they were purchased at. The value of the holding in PHARM.AS has increased by EUR 56,191 (USD $64,866) compared to the previous valuation of Pharming Group NV however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 82.6152 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 82.6152. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 4,626 (USD $5,340) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PINC - Premier Inc | HOLD | 0 @ USD 28.17 | USD 0 | The current share valuation price of PINC based on adjusted close was USD 28.17. The average price that PINC shares were previous bought at was USD 26.81. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in PINC has increased by USD 1,996 compared to the previous valuation of Premier Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 167.963 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 167.963. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 304,218 (USD $197,815) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 320.35 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 320.35. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 26,572 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 167.89 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 167.89. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 325.9% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 8,147 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 72.48 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 72.48. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 47.4% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 67,253 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 19.73 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 19.73. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -33.4% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 50,822 compared to the previous valuation of Quidel Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 43.1435 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 43.1435. The average price that QIA.DE shares were previous bought at was EUR 40.6149. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 16,475 (USD $19,019) compared to the previous valuation of QIAGEN NV |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 19.46 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 19.46. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 123.9% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 13,533 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 145.66 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 145.66. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 181,498 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 11.02 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 11.02. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 31.5% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 10,367 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 6.17 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 6.17. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 62.4% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 20,787 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 359.601 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 359.601. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 22,916 (USD $28,393) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 345.837 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 345.837. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 538,375 (USD $667,057) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 92.28 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 92.28. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in RVTY has increased by USD 215,442 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.51 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.51. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is -12.6% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 53,287 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 97.63 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 97.63. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 52.3% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 190,016 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 18.29 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 18.29. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -22.1% lower than average price they were purchased at. The value of the holding in SDGR has increased by USD 36,270 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 30.073 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 30.073. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 137,308 (USD $14,392) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 92.6282 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 92.6282. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -25.7% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 2,545 (USD $3,153) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 17.18 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 17.18. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -35.7% lower than average price they were purchased at. The value of the holding in SLP has increased by USD 928 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 17.27 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 17.27. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -70.0% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 42,883 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 259.796 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 259.796. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 88,248 (USD $101,872) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 22.37 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 22.37. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 92.4% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 32,416 compared to the previous valuation of Stoke Therapeutics Inc |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 45.4 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 45.4. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 29.9% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 42,457 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 54.0403 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 54.0403. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -2.5% lower than average price they were purchased at. The value of the holding in SXS.L has increased by GBP 7,021 (USD $9,227) compared to the previous valuation of Spectris PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 57.46 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 57.46. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in TECH has increased by USD 9,577 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 165.168 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 165.168. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -18.6% lower than average price they were purchased at. The value of the holding in TECN.SW has fallen by CHF 40,762 (USD $50,505) compared to the previous valuation of |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 30.3 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 30.3. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 337,498 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 576.35 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 576.35. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 41.3% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 142,388 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 16.37 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 16.37. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -25.9% lower than average price they were purchased at. The value of the holding in TNDM has increased by USD 8,835 compared to the previous valuation of Tandem Diabetes Care Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 30.96 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 30.96. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -27.8% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 45,909 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 17.08 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 17.08. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 246,393 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 17.08 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 17.08. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 246,393 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 258.873 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 258.873. The average price that UCB.BR shares were previous bought at was EUR 188.363. The current market price is 37.4% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 276,651 (USD $319,363) compared to the previous valuation of UCB SA |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.35 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.35. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 35.2% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 58,799 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.37 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.37. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -33.2% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 29,981 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.37 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.37. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -33.2% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 29,981 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.2953 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.2953. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 50.1% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 10,444 (USD $12,056) compared to the previous valuation of Valneva SE however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.42 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.42. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in VNDA has increased by USD 1,382 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 27.65 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 27.65. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 40.7% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 20,957 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 17.4709 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 17.4709. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -59.1% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 5,517 (USD $578) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 18.05 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 18.05. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 26.2% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 99,857 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
Value of shares added and average price calculated using the adjusted close on the day which may not be the price the ETF paid for the shares or sold the share at